Status and phase
Conditions
Treatments
About
This is a correlative study to characterize serum metabolites associated with bone deposition, growth and turnover in patients with newly diagnosed metastatic CRPC who are not currently receiving bone targeting agents.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Histologic proof of adenocarcinoma of the prostate with clinical evidence of metastatic disease to the bone.
Castrate resistant progression of prostate carcinoma, as shown by:
Serum testosterone level <50 ng/dL or prior bilateral orchiectomy. Treatment to maintain castrate levels of testosterone should continue, and
Patients with nodal disease are eligible.
Bi-dimensionally measurable disease within the bone.
Life expectancy of at least 12 weeks.
ECOG Performance status < 2
Adequate:
CLcr = [(140-age) x wt (kg)]/[72 x serum creatinine (mg/dL)].
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
1 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal